Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Kezar Life Sciences Inc KZR

Healthcare Biotechnology
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company’s lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and... see more

Recent & Breaking News (NDAQ:KZR)

Kezar Life Sciences Reports Third Quarter 2025 Financial Results

Business Wire November 12, 2025

Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2025

Business Wire November 7, 2025

Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives

Business Wire October 16, 2025

Kezar Life Sciences to Participate in Two Upcoming Investor Conferences

Business Wire August 28, 2025

Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update

Business Wire August 13, 2025

Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis

Business Wire July 15, 2025

Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference

Business Wire May 28, 2025

Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

Business Wire May 13, 2025

Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results

Business Wire March 25, 2025

Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025

Business Wire March 24, 2025

Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025

Business Wire February 18, 2025

Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Business Wire November 12, 2024

Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)

Business Wire November 5, 2024

Kezar Life Sciences Announces 1-for-10 Reverse Stock Split

Business Wire October 28, 2024

Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan

Business Wire October 17, 2024

Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update

Business Wire October 17, 2024

Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal

Business Wire October 10, 2024

Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis

Business Wire October 4, 2024

Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients

Business Wire September 30, 2024

Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Business Wire September 4, 2024